{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.9","upperLimit":"27.1","value":"6.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"Progression was assessed by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphoma. Progression is defined as ≥50% increase from nadir in the sum of the products of the perpendicular diameters (SPD) of any previously identified abnormal nodes for Partial Response's or non-responders. Progression-free survival (PFS) was determined from the on-study date until date of progression or last follow-up. The probability of PFS as a function of time was estimated by the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"All participants who received 3.4 mg/kg, 4.8 mg/kg, 8.5 mg/kg and 15 mg/kg siplizumab given on day 1 of each cycle followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab (EPOCH) (combo chemo) on days 1-5 for 21 days.","id":"OG000","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"Data collected from participants receiving different dose levels were combined and analyzed as a single Arm/Group as pre-specified in the study protocol.","reportingStatus":"POSTED","timeFrame":"On-study date until date of progression or last follow up, approximately 7 months.","title":"Overall Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}